

**28 March 2006**

### **H2O APPOINTS ADVISORY PANEL FROM ACADAEMIA AND INDUSTRY.**

H2O has now appointed six members to its advisory panel, who will bring experience from both research and industry to benefit the company.

Professor Sir Patrick Bateson, Emeritus Professor of Ethology at Cambridge University and formerly Provost of King's College, Cambridge, is President of the Zoological Society of London and was Vice-Chairman of the Museums and Galleries Commission. Elected a Fellow of the Royal Society of London in 1983, he became its Biological Secretary and Vice-President (1998–2005). He is one of the leading scientists in the country, with an outstanding international reputation.

Professor Professor Peter Dobson, Professor of Engineering, is Science and Academic Director of the Oxford University Begbroke Science Park. Peter has extensive experience with spin-off companies, including Oxonica plc, a specialist company making nanoparticles for a wide range of applications, and Oxford Biosensors Ltd, makers of a hand-held device based on enzyme-functionalised microelectrode arrays.

Professor Peter Ratcliffe, FRS, is Head of the Clinical Division of the Nuffield Department of Medicine at the University of Oxford. He has extensive research experience, publishing over 150 peer-reviewed manuscript. In 2005 Peter co-founded ReOx, a biotechnology spinout from the University of Oxford. He was elected to the Fellowship of the Royal Society in 2002.

Mr Max Alexander has expert commercial experience of the telecoms, media and information technology sectors. Max started his career as a consultant at McKinsey after gaining a BA in PPE from University College, Oxford. He has been in senior positions at companies such as Thomson Directories, Carphone Warehouse and TalkTalk. He has also worked as a consultant to media and sports businesses, including Flextech, Granada, Manchester United and the Premier League.

Mr Brian Ashford-Russell is one of the leading specialists in global technology investing over the last 20 years. He has managed a number of top performing funds including Henderson (previously TR) Global technology unit trust, and the TR and Henderson technology investment trusts. He co-founded and is a director of Polar Capital Partners, a specialist fund manager.

Dr John King has more than 30 years' experience of the pharmaceutical sector, having joined Galen Pharmaceutical in 1979. Following the acquisition of Warner Chilcott Inc in 2000, he transformed Galen into a United States Speciality Pharmaceutical Company, culminating in the rebranding of the company to Warner Chilcott plc in 2004. He resigned as Chairman in 2005 and continues to act for the company as a non-executive director. John holds degrees from the Queens University of Belfast and is a member of both the Pharmaceutical society of Northern Ireland and Ireland.

**For further information, please call David Kelly or Paul Coleman on: +44 (0)1865 251 000 or email [Info@h2ovp.com](mailto:Info@h2ovp.com)**